Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.

Abstract: Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.

Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.

Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.

Abstract: Anti-TauC3 antibodies that are at least several orders of magnitude more specific for TauC3 than for full length tau (2N4R) are described. Also described are methods of using anti-TauC3 antibodies.

Abstract: The present invention relates to pharmaceutical compositions for use in the treatment or prevention of a C5-related disease and methods for treating or preventing a C5-related disease. The present invention further relates to dosages and administrations of anti-C5 antibody or pharmaceutical compositions containing the anti-C5 antibody.

Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Calcitonin Gene Related Peptide (CGRP). These anti-CGRP antibodies, or antigen-binding fragments thereof, have a high affinity for CGRP, function to inhibit CGRP, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human) and can be used to treat CGRP-associated disorders, while avoiding the adverse side effects associated with the current CGRP antagonist therapies.

Abstract: Disclosed herein are bispecific antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and to a T cell-specific or NK cell-specific receptor molecule, pharmaceutical compositions and kits containing the same, and methods of making and using the same.

Abstract: The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.

Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.

Abstract: Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NF?B activity, useful in treatment of IL-

Abstract: A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.

Abstract: Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.

Abstract: The present invention provides fusion proteins containing cytokines and novel CD47 antibodies or immunologically active fragments thereof, as well as pharmaceutical compositions containing such fusion proteins that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation. These fused proteins have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination.

Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.

Abstract: The present invention provides a composition comprising a first antibody molecule that specifically recognizes CD3 and a second antibody molecule that specifically recognizes CD7, for use in a method of treatment, or preventative treatment of viral infection or viral reactivation in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety. Also provided is a method of treating a mammalian subject having, or being at risk of developing, chronic Graft versus Host disease (cGVHD). Also provided is a related pharmaceutical composition.

Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Abstract: The present invention relates to antagonistic antigen binding proteins, a nucleic acid encoding the antagonistic binding protein, a recombinant expression vector comprising the nucleic acid molecule, a host cell comprising the vector, a method of making the antagonistic antigen binding protein, an antagonistic binding protein produced by the method and a pharmaceutical composition comprising the antagonistic binding protein, the nucleic acid or the vector. The present invention further relates to a kit comprising the pharmaceutical composition and use of the antagonistic binding protein in the treatment of cancer and/or chronic infectious diseases.

Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.

Abstract: The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.

Abstract: The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist.

Abstract: The present disclosure relates to compositions and uses thereof for inhibiting epithelial cell proliferation by exposing an epithelial cell to an agent that inhibits P-selectin expression and/or activity.

Abstract: The present invention relates to methods of promoting growth of pancreatic islet cells, especially beta islet cells. In particular, the invention relates to methods of promoting growth of pancreatic islet cells by administration of HGF-MET agonists, such as MET agonist antibodies or fragments thereof. The invention further relates to HGF-MET agonists, such as MET agonist antibodies or fragments thereof, and pharmaceutical compositions comprising said agonists, for use in methods of the invention.

Abstract: The present invention relates to a recombinant protein with a nucleic acid binding domain. In particular, the present invention relates to a recombinant protein comprising a double stranded RNA (dsRNA) binding domain and a Cetuximab antibody; a complex further comprising dsRNA; a nucleic acid sequence; and a pharmaceutical composition comprising the recombinant protein or the complex of the invention and a pharmaceutically acceptable carrier. Further, the present invention relates to the recombinant protein, complex or pharmaceutical composition of the invention for use in the treatment of cancer, wherein said cancer is characterized by EGFR-overexpressing cells.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: It is intended to produce a cell expressing a mutant chimeric antigen receptor (CAR) having excellent cytotoxicity to target cells. The present invention provides a genetically modified cell having introduced thereinto a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain, and an intracellular signaling domain, wherein the tar get binding domain is a mutant having the substitution of glutamic acid at position 21 in the amino acid sequence shown in SEQ ID NO: 1 with another amino acid.

Abstract: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.

Abstract: Provided is a broad-spectrum, efficient and anti-tumor anti-TRAILR2 antibody-toxin-conjugate (ADC, named Zapadcine-1(a, b, c, d) and Zapadcine-3(a, b, c, d, e)). Toxin with cytotoxic effect is linked to an anti-TRAILR2 humanized monoclonal antibody by means of a covalent bond by using disulfide bond bridging or conventional coupling technology and chemical linkers, so as to form an anti-TRAILR2 humanized antibody-toxin-conjugate. The ADC has the specificity of TRAILR2 positive tumors, and after conjugated to TRAILR2, the positive tumors can be endocytosed into lysosomes of tumor cells, and is degraded by means of proteases inside the lysosomes to release free micromolecule urotoxins, so that different TRAILR2 positive tumor cells are killed specifically, the tumor growth is suppressed, the tumor cells are even completely eliminated, and the tumor is cured.

Abstract: In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+non-cancer cells. In a further aspect, the present disclosure relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the receptor as well as vectors and cells containing the same. Finally, the present disclosure relates to the use of the chimeric antigen receptor for use in improving persistence and amplification of lymphocyte containing the same and the use of specific peptides for improving persistence and amplification of genetically modified lymphocytes expressing the same.

Abstract: The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.

Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.

Abstract: The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.

Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

Abstract: The present invention relates to the field of proteases. More specifically, the present invention provides compositions and methods useful for profiling protease activity using phage display. In one embodiment, a display vector useful for profiling protease activity comprises a nucleic acid sequence encoding (a) a peptide to be displayed on the surface of the vector; (b) a first affinity tag C-terminal to the peptide; and (c) a second affinity tag N-terminal to the peptide. The display vector can comprise a virus, bacteriophage, yeast, bacteria, retrovirus, ribosome or mRNA. In particular embodiments, the peptide comprises a human peptidome library peptide.

Abstract: A neutral salt consisting of a polyaminosaccharide cation and an anion, as well as a procedure for the preparation of the neutral salt and uses thereof as a biomaterial and as an ingredient in pharmaceutical compositions are disclosed. Indeed, said neutral salt has surprisingly exhibited high water-solubility and high purity, the preparation procedure having minimised the content of high-risk contaminants in the final product and reduced reaction and purification times.

Abstract: The present disclosure relates to a process for preparing alkali metal salt of carboxyalkyl ether of tamarind gum with one or more improved properties like improved viscosities and electrolytic stability. Particularly the present disclosure provides a process for preparing alkali metal salt of carboxyalkyl ether of tamarind gum comprising: (a) permeating a pulverized tamarind gum powder by mercerizing said pulverized tamarind gum powder in the presence of an alkali, and a non-aqueous organic polar solvent present in an amount of at least 2 times the amount of the tamarind gum v/w; (b) carrying out etherification of alkali-tamarind gum with etherifying agent to provide an alkali metal salt of carboxyalkyl ether of tamarind gum; in which, steps of mercerizing the pulverized tamarind gum powder and etherification are carried out separately or simultaneously.

Abstract: The invention provides a method for preparation of homopolymers and non-homopolymers comprising polymerizing in an aqueous medium a monomer comprising at least one acryloyl moiety and at least one functionalized or unfunctionalized lactam moiety, and optionally at least one hydrophilic or hydrophobic comonomer, in the presence of at least one chain transfer agent and at least one non-radiation initiator. Exemplerary diblock polymers prepared by the method have the structure: where subscripts x, y, and z and variables R, R8, R9 and R10 are described herein.

Abstract: The present invention is directed to a compound of formula I, wherein R1 comprises hydrogen, an alkyl group, or an aryl group; R2 comprises hydrogen or a methyl group; R3 comprises a divalent organic group; R4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R5), wherein R5 comprises a monovalent organic group. The present invention is also directed towards polymers comprising a pendant carbamate-functional moiety comprising the structure: wherein R1 comprises hydrogen, an alkyl group, or an aryl group; R2 comprises hydrogen or a methyl group; R3 comprises a divalent organic group; R4 comprises a divalent organic group; and X comprises oxygen, NH, or N(R5) wherein R5 comprises a monovalent organic group. The present invention is also directed to methods of preparing such compounds and polymers, compositions comprising such polymers, and coatings produced from such compositions.

Abstract: A photopolymerized prepolymer manufacturing system can create material suitable for 3D printing buildings or building components. The system can include a conveyor, a prepolymerization chamber, and one or more processors. The prepolymerization chamber can have multiple prepolymerization stations arranged in sequence and can convert untreated material into photopolymerized prepolymer material as the conveyor moves the prepolymer past the prepolymerization chamber. The processor(s) can control operations of the conveyor, the prepolymerization chamber, or both, to alter operations in response to a detected system event. Each polymerization station can include a light source, such as an LED array, that irradiates material. Each light source can be in a lid of the prepolymerization station. When operation of one polymerization station is halted, such as for maintenance, then the system can increase the light source intensity of the remaining polymerization stations, slow the conveyor speed, or both.

Abstract: A method for preparing cis-1,4-polydienes, the method comprising the steps of preparing a preformed, active lanthanide-based catalyst, aging the active lanthanide-based catalyst for more than 5 days to thereby formed an aged catalyst, and introducing the aged catalyst and conjugated diene monomer to be polymerized to thereby form an active polymerization mixture in which the conjugated diene monomer is polymerized to form a polydiene having a reactive chain end.

Abstract: In some embodiments, ethylene-propylene branched copolymers are synthesized with pyridyldiamido catalysts and a chain transfer agent, and their performance as viscosity modifiers in oil are detailed. In some embodiments, the present disclosure provides for ethylene-propylene branched copolymers having a shear thinning onset of less than about 0.01 rad/s and an HTHS value of less than about 3.3. In some embodiments, the ethylene-propylene branched copolymer is used as a viscosity modifier in a lubricating composition and a fuel composition.

Abstract: The present disclosure provides tunable fluoropolymers and methods for making them.

Abstract: An object of the present invention is to provide a radiation-sensitive resin composition being superior in each of an inhibitory ability of defects, LWR performance, and sensitivity. An aspect of the present invention is a radiation-sensitive resin composition containing: a polymer having a first structural unit represented by the following formula (1), and a second structural unit represented by the following formula (2) and having an acid-labile group; a first acid generating agent which generates a first acid upon irradiation with a radioactive ray; and a second acid generating agent which generates a second acid upon irradiation with a radioactive ray, wherein the first acid, to be generated from the first acid generating agent, disassociates the acid labile group in the polymer upon heating under a condition involving a temperature of no less than 80° C. and no greater than 140° C.